Health care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was down 0.17% while the iShares NASDAQ Biotechnology Index (IBB) was 0.14% higher recently.
Protagonist Therapeutics (PTGX) was slipping past 56% after saying the US Food and Drug Administration has placed a hold on the clinical studies of its drug candidate, rusfertide or PTG-300. The clinical hold comes after the company notified the agency of a recent non-clinical finding in a mouse model study wherein benign and malignant subcutaneous skin tumors have been observed.
AbCellera (ABCL) was up more than 16% after the company and Eli Lilly (LLY) said the US Food and Drug Administration has expanded the emergency use authorization for bamlanivamab administered with etesevimab to include the prevention of COVID-19 in people exposed to the SARS-CoV-2 virus.
Agenus (AGEN) was more than 8% higher after reporting final results from a phase 2 trial evaluating balstilimab in combination with zalifrelimab in patients with recurrent/metastatic cervical cancer demonstrating "high" response rates and "promising" overall survival results.